<DOC>
	<DOCNO>NCT02745145</DOCNO>
	<brief_summary>The purpose trial compare two dos abituzumab placebo determine whether abituzumab effective , safe , well tolerate provoke well immune response placebo treatment patient SSc-ILD already receive constant dos mycophenolate .</brief_summary>
	<brief_title>Abituzumab SSc-ILD</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<criteria>Subjects eligible trial fulfill follow inclusion criterion : Female male subject age 18 75 year age provide inform write consent . Subjects fulfil 2013 American College Rheumatology ( ACR ) /European League Against Rheumatism criterion classification systemic sclerosis ( SSc ) . Disease duration le ( &lt; ) 7 year first nonRaynaud 's symptom . According central reading : Diffusion capacity lung carbon monoxide ( DLCO ) great equal ( &gt; = ) 30 percent ( % ) predict , Forced vital capacity ( FVC ) 40 % 85 % predict , ratio FVC % predict Diffusion capacity lung carbon monoxide ( DLCO ) % predict &lt; 1.8 . If criterion meet , Highresolution compute tomography ( HRCT ) lung perform , must show least 5 % fibrosis subject eligible . Use mycophenolate ( MMF ) least 6 month screen visit . The dose must stable least 3 month prior screen range follow : MMF 1.5 3 gram/day , MPS 1080 2160 mg/day . Female subject childbearing potential must use highly effective method contraception prevent pregnancy 4 week randomization must agree continue practice adequate contraception duration participation trial ( last Safety FollowUp Visit ) . For purpose trial , woman childbearing potential define `` All female subject puberty unless postmenopausal least 2 year surgically sterile . '' Highly effective contraception define 2 barrier method ( eg , female diaphragm male condom ) ; 1 barrier method least one following : spermicide , hormonal method , intrauterine device . Note mycophenolate affect metabolism oral contraceptive may reduce effectiveness , woman receive mycophenolate use oral contraceptive birth control employ additional contraceptive method ( eg , male female barrier method ) . Any condition Investigator 's opinion constitute inappropriate risk contraindication participation trial could interfere trial objective , conduct , evaluation . Renal impairment ( glomerular filtration rate [ GFR ] &lt; 45 mL/minute ( min ) /1.73 square meter ( m^2 ) calculate Modification Diet Renal Disease equation ) calculate follow : GFR ( mL/min per 1.73 m^2 ) = 175* ( standardize serum creatinine ) ^1.154 * ( age ) ^0.203 * 1.212 ( black ) * 0.742 ( female ) Urine dipstick &gt; =3 plus protein urine protein : creatinine ratio ( &gt; ) 2 mg/mg . Known diagnosis obstructive lung disease/emphysema ( Forced Expiratory Volume [ FEV1 ] /FVC ratio &lt; 0.65 ) and/or significant emphysematous change screen HRCT . Other clinically significant abnormality HRCT attributable scleroderma emphysema define . Known diagnosis significant respiratory disorder . Pulmonary hypertension fulfills least one following : Current/planned treatment systemic therapy target Pulmonary arterial hypertension ( PAH ) pulmonary hypertension ; History transthoracic echocardiography show least one following : tricuspid regurgitation jet &gt; 2.8 m/sec , right atrial enlargement ( major dimension &gt; 53 mm ) , right ventricular enlargement ( mid cavity dimension &gt; 35 mm ) , moderate severe leave ventricular dysfunction ; Nterminal prohormone brain natriuretic peptide &gt; 3*Upper limit normal ( ULN ) . Current clinical diagnosis another inflammatory connective tissue disease ( eg , systemic lupus erythematosus , rheumatoid arthritis , ankylose spondylitis , dermato/polymyositis ) . Concomitant sclerodermaassociated myopathy , fibromyalgia , secondary Sjögren 's allow . Suspected/confirmed significant aspiration within previous 6 month , eg . clinically significant viral/bacterial/fungal infection , major episode infection require hospitalization . Treatment parenteral antiinfectives within 4 week prior/during Screening Period . Completion oral antiinfectives within 2 week Screening . Use oral antiinfectives Screening Period . Vaginal candidiasis , onychomycosis , chronically suppressed oral herpes simplex virus allow . Prophylaxis Pneumocystis jiroveci pneumonia permit . History of/positive Human immunodeficiency virus , hepatitis C antibody and/or polymerase chain reaction Hepatitis B surface antigen and/or hepatitis B core antibody ( total and/or Immunoglobulin M ) antibody screen . History of/current diagnosis active tuberculosis ( TB ) , untreated latent TB infection ( LTBI ) . Presence uncontrolled New York Heart Association Class 3 4 congestive heart failure . History cancer , except adequately treat ( ie , evidence recurrence within 5 year prior screen ) basal cell/squamous cell carcinoma skin ( ≤3 total lifetime ) carcinoma situ cervix . Known hypersensitivity abituzumab DS DP . Current smoker ( incl . ecigarettes ) / smoke within 4 week screen . Use agent mycophenolate consider Investigator immunomodulating , immunosuppressive , potential scleroderma diseasemodifying property within 6 month screen , e.g . pirfenidone , nintedanib , cyclophosphamide , methotrexate , azathioprine , leflunomide , calcineurin inhibitor , D penicillamine , Potaba , AIMSPRO . Hydroxychloroquine chloroquine permit dose stable least 4 week screen . Use systemic corticosteroid 10 mg/day prednisone equivalent within 4 week prior last dose study drug . Inhaled topical corticosteroid permit . Use biologic agent within 12 week 5 halflives , whichever longer , screen . History antiCD20 Bcell deplete therapy , eg , rituximab ocrelizumab . Use anticoagulant antiplatelet agent ( aspirin = &lt; 350 mg daily permit ) . Clinically significant predefined abnormality lab test : Aspartate aminotransferase , Alanine aminotransferase alkaline phosphatase level &gt; 2.5*ULN ; Total bilirubin &gt; 1.5*ULN ( due know Gilbert 's disease ) ; Hemoglobin &lt; 5.0 mmol/L ( 9 g/dL ) , white blood cell count &lt; 2.5*10^9/L , platelet &lt; 100*10^9/L ) ; International normalize ratio partial thromboplastin time &gt; 2.0*ULN ; Thyroidstimulating hormone &lt; 0.01 &gt; =7.1 mIU/L . Inability receive IV infusion . History alcohol/drug abuse 1 year prior screen . Pregnancy/breastfeeding/lactation within 3 month prior screen . History thrombotic , thromboembolic , abnormal bleed event include concomitant antiphospholipid antibody syndrome . Subjects know lupus anticoagulant and/or anticardiolipin and/or antib2 glycoprotein antibodies alone exclude . Legal incapacity/limited legal capacity . Receipt/planned live/attenuated vaccination within 12 week prior screen 3 month last dose study drug . Seasonal influenza vaccination inactivate vaccine formulation permit . Major surgery require hospitalization within 4 week prior screen , plan major surgery duration trial . Subjects lung resection . History of/planned major organ hematopoietic stem cell/marrow transplant . Other protocol define exclusion criterion could apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Double-Blind Method</keyword>
	<keyword>Interstitial Lung Diseases</keyword>
	<keyword>Systemic Scleroderma</keyword>
	<keyword>Abituzumab</keyword>
	<keyword>Mycophenolate</keyword>
	<keyword>Efficacy , Safety</keyword>
</DOC>